With Sonic, PIQ was set to get royalty revenue of about $40 USD per test.
With the new strategy PIQ set to get revenue $400 USD per test, but with increased cost, maybe $100 per test.
Not to understate the importance of early diagnosis of endometriosis of Eso cancer, but the clinical roadshow is suggesting Promarker-D at least annually for diabetics!
Ann: PromarkerD outperforms conventional tests--results published, page-8
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.010(2.70%) |
Mkt cap ! $58.86M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 37.0¢ | 35.5¢ | $89.35K | 246.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 99321 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 7502 | 1 |
View Market Depth
| Last trade - 15.58pm 16/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |